Sears, Catherine R.Peikert, TobiasPossick, Jennifer D.Naidoo, JarushkaNishino, MizukiPatel, Sandip P.Camus, PhilippeGaga, MinaGaron, Edward B.Gould, Michael K.Limper, Andrew H.Montgrain, Philippe R.Travis, William D.Rivera, M. Patricia2021-05-282021-05-282019-09-15Sears, C. R., Peikert, T., Possick, J. D., Naidoo, J., Nishino, M., Patel, S. P., Camus, P., Gaga, M., Garon, E. B., Gould, M. K., Limper, A. H., Montgrain, P. R., Travis, W. D., & Rivera, M. P. (2019). Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 200(6), e31–e43. https://doi.org/10.1164/rccm.201906-1202ST1073-449Xhttps://hdl.handle.net/1805/26045Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening pneumonitis. The diagnosis of ICI-pneumonitis is increasing; however, the biological mechanisms, clinical and radiologic features, and the diagnosis and management have not been well defined. Objectives: To summarize evidence, identify knowledge and research gaps, and prioritize topics and propose methods for future research on ICI-pneumonitis. Methods: A multidisciplinary group of international clinical researchers reviewed available data on ICI-pneumonitis to develop and refine research questions pertaining to ICI-pneumonitis. Results: This statement identifies gaps in knowledge and develops potential research questions to further expand knowledge regarding risk, biologic mechanisms, clinical and radiologic presentation, and management of ICI-pneumonitis. Conclusions: Gaps in knowledge of the basic biological mechanisms of ICI-pneumonitis, coupled with a precipitous increase in the use of ICIs alone or combined with other therapies, highlight the importance in triaging research priorities for ICI-pneumonitis.en-USlung cancerimmunotherapyinterstitial lung diseaseNSCLCArticle